RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY FIMEI S.P.A
January 07, 2019 at 07:54 pm IST
Share
RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY FIMEI S.P.A.
Milan, 07 January 2019 - Pursuant to art. 144-octies, paragraph 1 of Consob's Regulation 11971/1999 ("Issuers' Regulations") and with reference to the Ordinary General Meeting of the Shareholders to be held on 5th February 2019 in a single call, RECORDATI S.p.A. informs that the slate for the appointment of the Directors filed by the majority shareholder, Fimei S.p.A., which owns 51.79% of RECORDATI S.p.A. share capital is available to the public at the Company's registered offices, on the "1info" storage mechanism(www.1info.it)and on the Company's website(www.recordati.it - section Investors, Shareholders' Meetings).
Please note that the above mentioned list is available jointly with the relevant documentation requested by law and by the Company's By-laws.
Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.
For further information:
Recordati website:www.recordati.com
Investor Relations
Media Relations
Marianne Tatschke
Studio Noris Morano
(39)0248787393
(39)0276004736, (39)0276004745
e-mail:investorelations@recordati.it
e-mail:norismorano@studionorismorano.com
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
Sede Legale
VIA M. CIVITALI, 1
CAPITALE SOCIALE € 26.140.644,50 I.V.
20148 MILANO, ITALIA
REG. IMP. MILANO N. 00748210150
TEL. (39) 0248787.1
CODICE FISCALE/P.IVA 007482210150
FAX (39) 0240073747
R.E.A. MILANO N. 401832
Attachments
Original document
Permalink
Disclaimer
Recordati S.p.A. published this content on 07 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 07 January 2019 14:23:08 UTC
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
RECORDATI 
